- Home
- IDYA vs TUYA Comparison
IDYA vs TUYA Comparison
Compare IDYA & TUYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- TUYA
- Stock Information
- Founded
- IDYA 2015
- TUYA 2014
- Country
- IDYA United States
- TUYA China
- Employees
- IDYA N/A
- TUYA N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- TUYA Computer Software: Prepackaged Software
- Sector
- IDYA Health Care
- TUYA Technology
- Exchange
- IDYA Nasdaq
- TUYA Nasdaq
- Market Cap
- IDYA 2.0B
- TUYA 1.7B
- IPO Year
- IDYA 2019
- TUYA 2021
- Fundamental
- Price
- IDYA $21.67
- TUYA $2.35
- Analyst Decision
- IDYA Strong Buy
- TUYA
- Analyst Count
- IDYA 12
- TUYA 0
- Target Price
- IDYA $54.27
- TUYA N/A
- AVG Volume (30 Days)
- IDYA 1.2M
- TUYA 2.4M
- Earning Date
- IDYA 08-05-2025
- TUYA 05-20-2025
- Dividend Yield
- IDYA N/A
- TUYA 4.65%
- EPS Growth
- IDYA N/A
- TUYA N/A
- EPS
- IDYA N/A
- TUYA 0.03
- Revenue
- IDYA $7,000,000.00
- TUYA $311,642,000.00
- Revenue This Year
- IDYA $101.20
- TUYA $11.65
- Revenue Next Year
- IDYA $286.70
- TUYA $13.06
- P/E Ratio
- IDYA N/A
- TUYA $70.07
- Revenue Growth
- IDYA N/A
- TUYA 27.64
- 52 Week Low
- IDYA $13.45
- TUYA $1.28
- 52 Week High
- IDYA $44.42
- TUYA $4.63
- Technical
- Relative Strength Index (RSI)
- IDYA 58.21
- TUYA 41.19
- Support Level
- IDYA $21.09
- TUYA $2.50
- Resistance Level
- IDYA $22.50
- TUYA $2.74
- Average True Range (ATR)
- IDYA 0.97
- TUYA 0.14
- MACD
- IDYA -0.04
- TUYA -0.03
- Stochastic Oscillator
- IDYA 56.44
- TUYA 4.00
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About TUYA Tuya Inc. each representing one
Tuya Inc is an IoT cloud development platform with a mission to build an IoT developer ecosystem and enable everything to be smart. The Company has pioneered a purpose-built IoT cloud development platform that delivers a full suite of offerings, including platform-as-a-service (PaaS) and Software-as-a-service (SaaS), to businesses and developers. Through its IoT cloud development platform, it has enabled developers to activate a vibrant IoT ecosystem of brands, OEMs, partners, and end users to engage and communicate through a broad range of smart devices. The company's revenue is derived from the PRC.